JP2010514787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514787A5 JP2010514787A5 JP2009544230A JP2009544230A JP2010514787A5 JP 2010514787 A5 JP2010514787 A5 JP 2010514787A5 JP 2009544230 A JP2009544230 A JP 2009544230A JP 2009544230 A JP2009544230 A JP 2009544230A JP 2010514787 A5 JP2010514787 A5 JP 2010514787A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- administered
- item
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 229960004768 irinotecan Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 201000006491 bone marrow cancer Diseases 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000010453 lymph node cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 18
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87186506P | 2006-12-26 | 2006-12-26 | |
| US60/871,865 | 2006-12-26 | ||
| PCT/US2007/088645 WO2008083101A1 (en) | 2006-12-26 | 2007-12-21 | Phosphoramidate alkylator prodrugs for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514787A JP2010514787A (ja) | 2010-05-06 |
| JP2010514787A5 true JP2010514787A5 (cg-RX-API-DMAC7.html) | 2012-02-02 |
| JP5357049B2 JP5357049B2 (ja) | 2013-12-04 |
Family
ID=39588979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544230A Expired - Fee Related JP5357049B2 (ja) | 2006-12-26 | 2007-12-21 | 癌の治療のためのフォスフォルアミデートアルキル化剤プロドラッグ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8552048B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2114157B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5357049B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2884044T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008083101A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| EP1896040B1 (en) | 2005-06-29 | 2012-08-01 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| ES2884674T3 (es) * | 2008-10-21 | 2021-12-10 | Immunogenesis Inc | Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed |
| MX2012014416A (es) * | 2010-06-28 | 2013-02-27 | Threshold Pharmaceuticals Inc | Tratamiento de cancer de sangre. |
| MX2012014428A (es) | 2010-07-12 | 2013-03-05 | Threshold Pharmaceuticals Inc | Administracion de profarmacos activados por hipoxia y de agentes antiangiogenicos para el tratamiento de cancer. |
| KR20140038390A (ko) * | 2011-04-01 | 2014-03-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| WO2012142520A2 (en) * | 2011-04-15 | 2012-10-18 | Threshold Pharmaceuticals, Inc. | Unit dose form for oral administration |
| JP2015500885A (ja) * | 2011-12-22 | 2015-01-08 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
| US20160045522A1 (en) * | 2012-02-21 | 2016-02-18 | Threshold Pharmaceuticals, Inc. | Treatment of Cancer |
| US9278124B2 (en) | 2012-10-16 | 2016-03-08 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| US10037382B2 (en) | 2012-10-29 | 2018-07-31 | Kyocera Corporation | Surface acoustic wave sensor |
| WO2015013448A1 (en) | 2013-07-26 | 2015-01-29 | Threshold Pharmaceuticals, Inc. | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| US10131683B2 (en) | 2014-07-17 | 2018-11-20 | Molecular Templates, Inc. | TH-302 solid forms and methods related thereto |
| SG11201707293VA (en) | 2015-03-10 | 2017-10-30 | Ascenta Pharmaceuticals Ltd | Dna alkylating agents |
| BR112017021167A2 (pt) | 2015-04-02 | 2018-07-03 | Obi Pharma, Inc. | composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i |
| PL412787A1 (pl) | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
| WO2016210175A1 (en) | 2015-06-24 | 2016-12-29 | Threshold Pharmaceuticals, Inc. | Aziridine containing dna alkylating agents |
| JP2019527236A (ja) | 2016-08-01 | 2019-09-26 | モレキュラー テンプレーツ，インコーポレイティド | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 |
| US20210283139A1 (en) | 2018-06-13 | 2021-09-16 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting uchl5 |
| WO2019238886A1 (en) | 2018-06-13 | 2019-12-19 | University Of Dundee | Bifunctional molecules for targeting usp14 |
| CA3103185A1 (en) | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| WO2020068347A1 (en) * | 2018-09-24 | 2020-04-02 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising cdc7 inhibitors |
| EP3650046A1 (en) | 2018-11-08 | 2020-05-13 | Cellis AG | Mesenchymal stem cell based targeted active ingredient delivery system |
| US20230174624A1 (en) | 2020-03-18 | 2023-06-08 | Cellis Ag | Ferritin variants with increased stability, complexation ability and transferrin receptor affinity |
| CA3212386A1 (en) | 2021-03-18 | 2022-09-22 | Alessandro ARCOVITO | Ferritin variants with increased stability and complexation ability |
| US20240366640A1 (en) * | 2021-08-27 | 2024-11-07 | Ascentawits Pharmaceuticals, Ltd. | Lyophilized formulation solution and lyophilized formulation, and method and use thereof |
| JP7762796B2 (ja) * | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| CN118829436A (zh) | 2022-03-15 | 2024-10-22 | 深圳艾欣达伟医药科技有限公司 | 治疗brca突变癌症患者的方法 |
| US20250295677A1 (en) | 2022-04-15 | 2025-09-25 | Ascentawits Pharmaceuticals, Ltd. | Method for treating cancer by using th-302 alone or in combination with parp inhibitor |
| WO2023226959A1 (zh) | 2022-05-23 | 2023-11-30 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| JP2025532550A (ja) | 2022-09-13 | 2025-10-01 | セリス アーゲー | 神経膠腫の処置用の単離標的化送達系 |
| WO2024061346A1 (zh) | 2022-09-22 | 2024-03-28 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| EP4637829A1 (en) | 2022-12-20 | 2025-10-29 | Cellis Sp. z o.o. ([Ltd.] | Isolated targeted delivery system for the treatment of ovarian cancer |
| WO2024179467A1 (zh) * | 2023-02-27 | 2024-09-06 | 深圳艾欣达伟医药科技有限公司 | 溶液、冻干制剂、冻干制剂单位包装、注射液及注射液配制方法 |
| WO2025083276A1 (en) | 2023-10-19 | 2025-04-24 | Cellis Ag | Improved isolated targeted delivery system |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652579A (en) * | 1969-06-26 | 1972-03-28 | Hoffmann La Roche | 1-methyl-2-substituted 5-nitroimidazoles |
| DE2229248C3 (de) | 1971-07-30 | 1980-03-27 | Gruppo Lepetit S.P.A., Mailand (Italien) | 5-Iminomethyl-2-nitroimidazoI-Derivate und Verfahren zu deren Herstellung |
| US4921963A (en) * | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| JPH0819111B2 (ja) * | 1987-10-22 | 1996-02-28 | ポーラ化成工業株式会社 | ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 |
| US4908356A (en) * | 1988-05-25 | 1990-03-13 | Research Corporation Technologies, Inc. | Aldophosphamide derivatives useful as antitumor agents |
| US5403932A (en) * | 1988-05-25 | 1995-04-04 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| US5190929A (en) * | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
| DE3835772A1 (de) * | 1988-10-20 | 1990-04-26 | Deutsches Krebsforsch | Tumorhemmende saccharid-konjugate |
| JP2626727B2 (ja) * | 1990-01-26 | 1997-07-02 | ポーラ化成工業株式会社 | ２―ニトロイミダゾール誘導体、その製造法及びこれを有効成分とする放射線増感剤 |
| US5233031A (en) * | 1991-09-23 | 1993-08-03 | University Of Rochester | Phosphoramidate analogs of 2'-deoxyuridine |
| WO1993008288A1 (en) * | 1991-10-23 | 1993-04-29 | Cancer Research Campaign Technology Limited | Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form |
| US5750782A (en) * | 1992-11-27 | 1998-05-12 | Cancer Research Campaign Technology Limited | Nitroaniline derivatives and their use as anti-tumour agents |
| US5306727A (en) | 1993-04-30 | 1994-04-26 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| JPH08510469A (ja) * | 1993-05-25 | 1996-11-05 | オークランド ユニサービシーズ リミテッド | ニトロベンジルマスタード四級塩およびその低酸素選択性細胞毒剤としての利用 |
| EP0648503B1 (en) | 1993-09-22 | 2000-07-26 | Hoechst Aktiengesellschaft | Pro-prodrugs, their production and use |
| JPH07309761A (ja) * | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5659061A (en) | 1995-04-20 | 1997-08-19 | Drug Innovation & Design, Inc. | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
| GB9516943D0 (en) * | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
| US6218519B1 (en) * | 1996-04-12 | 2001-04-17 | Pro-Neuron, Inc. | Compounds and methods for the selective treatment of cancer and bacterial infections |
| US6130237A (en) * | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| US6251933B1 (en) * | 1996-12-13 | 2001-06-26 | The Cancer Research Campaign Technology Limited | Seco precursors of cyclopropylindolines and their use as prodrugs |
| DE19720312A1 (de) * | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| US6240925B1 (en) * | 1999-03-23 | 2001-06-05 | Cynosure, Inc. | Photothermal vascular targeting with bioreductive agents |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| JP4629238B2 (ja) * | 1999-05-24 | 2011-02-09 | サザン・リサーチ・インスティテュート | イソホスホアミドマスタード・アナログ及びその使用 |
| WO2001004130A1 (en) * | 1999-07-14 | 2001-01-18 | Purdue Research Foundation | Phosphoramide compounds |
| ATE317846T1 (de) * | 2000-03-31 | 2006-03-15 | Purdue Research Foundation | Phosphoramidat-prodrugs |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US6506739B1 (en) * | 2001-05-01 | 2003-01-14 | Telik, Inc. | Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| FR2825926A1 (fr) | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR20030067275A (ko) | 2002-02-07 | 2003-08-14 | 주식회사 하이폭시 | 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제 |
| GB0306907D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Boireductively-activated prodrugs |
| GB0306908D0 (en) | 2003-03-26 | 2003-04-30 | Angiogene Pharm Ltd | Bioreductively activated stilbene prodrugs |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| US6855695B2 (en) * | 2003-06-13 | 2005-02-15 | Vion Pharmaceuticals, Inc. | Water-soluble SHPs as novel alkylating agents |
| BRPI0416085A (pt) | 2003-10-31 | 2007-01-02 | Auckland Uniservices Ltd | álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos |
| EP1711188B1 (en) | 2004-02-06 | 2012-06-06 | Threshold Pharmaceuticals, Inc. | Anti-cancer therapies |
| AU2005309761A1 (en) | 2004-11-22 | 2006-06-01 | Threshold Pharmaceuticals, Inc. | Tubulin binding anti cancer agents and prodrugs thereof |
| EP1896040B1 (en) * | 2005-06-29 | 2012-08-01 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| KR100755435B1 (ko) * | 2005-10-04 | 2007-09-04 | 삼성전자주식회사 | 디지털 방송 제한 수신 단말기 및 그 방법 |
| WO2008011588A2 (en) | 2006-07-20 | 2008-01-24 | Threshold Pharmaceuticals, Inc. | Glycoconjugates of phosphoramidate alkylators for treatment of cancer |
| WO2008076826A1 (en) | 2006-12-13 | 2008-06-26 | Threshold Pharmaceuticals, Inc. | Pyrophosphoramide alkylators |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
-
2007
- 2007-12-21 EP EP07869800.8A patent/EP2114157B1/en active Active
- 2007-12-21 ES ES07869800T patent/ES2884044T3/es active Active
- 2007-12-21 US US12/521,290 patent/US8552048B2/en active Active
- 2007-12-21 JP JP2009544230A patent/JP5357049B2/ja not_active Expired - Fee Related
- 2007-12-21 WO PCT/US2007/088645 patent/WO2008083101A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514787A5 (cg-RX-API-DMAC7.html) | ||
| Jones Jr et al. | Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. | |
| JP2012506448A5 (cg-RX-API-DMAC7.html) | ||
| Sakamoto et al. | Paclitaxel chemotherapy for the treatment of gastric cancer | |
| JP2009513662A5 (cg-RX-API-DMAC7.html) | ||
| JP2013523656A5 (cg-RX-API-DMAC7.html) | ||
| RU2015139901A (ru) | Комбинированная терапия с использованием антител против клаудина 18.2 для лечения рака | |
| RU2014152107A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| JP2013503174A5 (cg-RX-API-DMAC7.html) | ||
| JP2019521180A5 (cg-RX-API-DMAC7.html) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| JP2012522837A5 (cg-RX-API-DMAC7.html) | ||
| JP2017516802A5 (cg-RX-API-DMAC7.html) | ||
| JP2016515586A5 (cg-RX-API-DMAC7.html) | ||
| Nabell et al. | Docetaxel with concurrent radiotherapy in head and neck cancer | |
| JP2009536956A (ja) | 抗癌治療法 | |
| Lee et al. | S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial | |
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| JP2019038797A5 (cg-RX-API-DMAC7.html) | ||
| Belani | Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations | |
| Zhou et al. | Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma | |
| CN1917885A (zh) | 抗癌疗法 | |
| Michels et al. | A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer | |
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| JP2016503035A5 (cg-RX-API-DMAC7.html) |